title: Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
abstract: Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.
authors.affiliation: Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. j.verweij@erasmusmc.nl
authors.forename: Jaap
authors.initials: J
authors.lastname: Verweij
authors.forename: Paolo G
authors.initials: PG
authors.lastname: Casali
authors.forename: Dusan
authors.initials: D
authors.lastname: Kotasek
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
authors.forename: Peter
authors.initials: P
authors.lastname: Reichard
authors.forename: Ian R
authors.initials: IR
authors.lastname: Judson
authors.forename: R
authors.initials: R
authors.lastname: Issels
authors.forename: Allan T
authors.initials: AT
authors.lastname: van Oosterom
authors.forename: Martine
authors.initials: M
authors.lastname: Van Glabbeke
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate